Compare BYFC & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BYFC | RFL |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 63.5M |
| IPO Year | 2013 | 2017 |
| Metric | BYFC | RFL |
|---|---|---|
| Price | $7.48 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.5K | ★ 57.2K |
| Earning Date | 04-27-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | $184,000.00 | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 18.71 | ★ 43.96 |
| 52 Week Low | $5.51 | $1.12 |
| 52 Week High | $8.85 | $3.19 |
| Indicator | BYFC | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 38.21 | 48.29 |
| Support Level | $7.19 | $1.15 |
| Resistance Level | $7.54 | $1.32 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 26.46 | 31.66 |
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.